Best Selling Reliable Quality Raw Material 99% Powder CAS 302-79-4 Vitamin a Acid/Tretinoin/Retinoic Acid for Skincare

• Type: Skin Care
• Function: Acne Treatment
• Main Ingredient: Retinoic Acid
• Group: Female
• Certification: MSDS, Coa
• Quality Guarantee Period: Two Years
• Model NO.: A-38
• Store Method: Normal Temperature
• Cosmetics Approval No.: -
• Sample: Available
• MOQ: 10g
• Shelf Life: 2 Years
• Test Method: HPLC
• Assay: 99%
• Appearance: Yellow Powder
• Package: PE Bag+Aluminum Foil Bag
• Storage: Cool&Dry Places
• CAS No.: 302-79-4
• Molecular Formula: C20h28o2
• Molecular Weight: 300.44
• Grade: Cosmetic&Pharmaceutical Grade
• Application: Cosmetic&Pharmaceutical
• Brand Name: Greenway
• Certificate: ISO
• Transport Package: 1kg/Bag; 25kg/Drum
• Specification: 1kg/Bag; 25kg/Drum
• Trademark: Greenway
• Origin: Jiangsu
• HS Code: 2942000000
• Production Capacity: 100kg/Month

Product Description

Product Name	Retinoic Acid
Other Names	Vitamin A Acid/Tretinion/Tretinoin
CAS No.	302-79-4
Molecular Formula	C20H28O2
Molecular Weight	300.44
Appearance	Yellow Powder
Assay	99%
Grade	Cosmetic&Pharmaceutical Grade
Brand Name	Greenway

Product Introduction:

Tretinoin is the acid form of vitamin A and is also known as all-trans retinoic acid or ATRA. It is a drug commonly used to treat acne vulgaris and keratosis pilaris. It is available as a cream or gel It is also used to treat acute promyelocytic leukemia. It is also available as a generic.

 

Its success in treating acute promyelocytic leukemia was a major breakthrough in the treatment of this type of leukemia.It works in APL because the majority of cases involve a chromosomal translocation of chromosomes 15 and 17, which causes genetic fusion of the retinoic acid receptor gene to the promyelocytic leukemia  gene.

 

This fusion PML-RAR protein is responsible for preventing immature myeloid cells from differentiating into more mature cells. This block in differentiation is thought to cause leukemia.

 

ATRA acts on PML-RAR to lift this block, causing the immature promyelocytes to differentiate to normal mature blood cells thus decreasing promyelocytes.